stoxline Quote Chart Rank Option Currency Glossary
  
Indivior PLC (INDV)
16.79  0.7 (4.35%)    06-21 16:00
Open: 16.61
High: 16.975
Volume: 149,757
  
Pre. Close: 16.09
Low: 16.48
Market Cap: 2,253(M)
Technical analysis
2024-06-21 4:53:11 PM
Short term     
Mid term     
Targets 6-month :  20.46 1-year :  21.71
Resists First :  17.52 Second :  18.59
Pivot price 16.95
Supports First :  15.8 Second :  13.14
MAs MA(5) :  16.32 MA(20) :  17.14
MA(100) :  18.92 MA(250) :  19.48
MACD MACD :  -0.5 Signal :  -0.5
%K %D K(14,3) :  16 D(3) :  11
RSI RSI(14): 46
52-week High :  24.89 Low :  14.38
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ INDV ] has closed above bottom band by 44.7%. Bollinger Bands are 2.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.99 - 17.06 17.06 - 17.13
Low: 16.3 - 16.37 16.37 - 16.45
Close: 16.66 - 16.77 16.77 - 16.9
Company Description

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Headline News

Mon, 24 Jun 2024
Indivior PLC Executes Share Buyback Plan - TipRanks

Sun, 23 Jun 2024
Indivior (NASDAQ:INDV) Shares Gap Up to $16.09 - Defense World

Sat, 22 Jun 2024
Objective long/short (INDV) Report - Stock Traders Daily

Fri, 21 Jun 2024
Indivior (NASDAQ:INDV) Shares Gap Up to $16.09 - MarketBeat

Fri, 21 Jun 2024
Indivior PLC Executes Share Buyback Plan - TipRanks

Tue, 18 Jun 2024
Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene ... - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 135 (M)
Shares Float 119 (M)
Held by Insiders 3.2 (%)
Held by Institutions 85.8 (%)
Shares Short 123 (K)
Shares Short P.Month 202 (K)
Stock Financials
EPS 0.03
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.07
Profit Margin 0.4 %
Operating Margin 22.8 %
Return on Assets (ttm) 9.9 %
Return on Equity (ttm) 12.1 %
Qtrly Rev. Growth 12.3 %
Gross Profit (p.s.) 0
Sales Per Share 8.32
EBITDA (p.s.) 1.98
Qtrly Earnings Growth 9.6 %
Operating Cash Flow -334 (M)
Levered Free Cash Flow -87 (M)
Stock Valuations
PE Ratio 419.75
PEG Ratio 0
Price to Book value 239.85
Price to Sales 2.01
Price to Cash Flow -6.77
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android